INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $906 | -7.1% | 17,400 | +13.0% | 0.01% | 0.0% |
| Q2 2023 | $975 | +52.6% | 15,400 | +30.5% | 0.01% | +25.0% |
| Q1 2023 | $639 | +2.4% | 11,800 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $624 | -99.9% | 11,800 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $549,000 | -18.5% | 11,800 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $674,000 | -6.6% | 11,800 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $722,000 | -10.4% | 11,800 | -23.4% | 0.00% | 0.0% |
| Q4 2021 | $806,000 | +40.4% | 15,400 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $574,000 | -8.7% | 15,400 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $629,000 | +62.5% | 15,400 | +35.1% | 0.00% | +50.0% |
| Q1 2021 | $387,000 | +6.6% | 11,400 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $363,000 | +23.9% | 11,400 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $293,000 | -50.0% | 11,400 | -50.0% | 0.00% | 0.0% |
| Q2 2020 | $586,000 | – | 22,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |